Tirzepatide (TZP) is a once-weekly GIP/GLP-1 receptor agonist for treating type 2 diabetes (T2D). In the SURPASS clinical trial program, TZP demonstrated significant HbA1C and body weight reductions versus placebo and comparators. The most common adverse events (AEs) in TZP-treated participants were gastrointestinal (GI) in nature. This post hoc analysis evaluated the impact of nausea, vomiting, or diarrhea AEs on weight loss with TZP across the SURPASS 1-5 trials. Mediation analyses were conducted to evaluate the contribution of direct and indirect (mediated by nausea, vomiting, or diarrhea) effects of TZP on weight change versus comparators. Superior weight loss with TZP appears to be independent of reported nausea, vomiting, or diarrhea AEs across the SURPASS 1-5 clinical trials.
